Terms: = Head and neck cancer AND TRIM33, RFG7, 51592, ENSG00000197323, Q9UPN9, TF1G, FLJ32925, TIF1G, PTC7, TIFGAMMA, TIF1GAMMA AND Treatment
3 results:
1. Deubiquitinase YOD1 suppresses tumor progression by stabilizing E3 ligase trim33 in head and neck squamous cell carcinoma.
Wu Y; Duan Y; Han W; Cao J; Ye B; Chen P; Li H; Wang Y; Liu J; Fang Y; Yue K; Wu Y; Wang X; Jing C
Cell Death Dis; 2023 Aug; 14(8):517. PubMed ID: 37573347
[TBL] [Abstract] [Full Text] [Related]
2. Anti-TIF1γ antibody-positive dermatomyositis associated with nivolumab administration in a patient with advanced oesophageal squamous cell carcinoma: A case report and literature review.
Sakurai T; Takahashi J; Komatsu T; Mitsumura H; Iguchi Y
Mod Rheumatol Case Rep; 2023 Jun; 7(2):416-421. PubMed ID: 36715286
[TBL] [Abstract] [Full Text] [Related]
3. Next-generation sequencing in salivary gland carcinoma: Targetable alterations lead to a therapeutic advantage-Multicenter experience.
Moore A; Bar Y; Maurice-Dror C; Ospovat I; Sarfaty M; Korzets Y; Goldvaser H; Gordon N; Billan S; Gutfeld O; Popovtzer A
Head Neck; 2020 Apr; 42(4):599-607. PubMed ID: 31762146
[TBL] [Abstract] [Full Text] [Related]
